Components of Placebo Effect: Randomised Controlled Trial in Patients with Irritable Bowel Syndrome

被引:0
|
作者
Hummelsberger, J. [1 ]
机构
[1] Chinese Med SMS Societas Med Sinensis, Int Soc, Hackenstr 7 C, D-80331 Munich, Germany
来源
DEUTSCHE ZEITSCHRIFT FUR AKUPUNKTUR | 2010年 / 53卷 / 02期
关键词
D O I
10.1016/j.dza.2010.04.011
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Objective: To investigate whether placebo effects can experimentally be separated into the response to three components - assessment and observation, a therapeutic ritual (placebo treatment), and a supportive patient- practitioner relationship - and then progressively combined to produce incremental clinical improvement in patients with irritable bowel syndrome. To assess the relative magnitude of these components. Design: A six week single blind three arm randomised controlled trial. Setting Academic medical centre. Participants 262 adults (76 % women), mean (SD) age 39 (14), diagnosed by Rome II criteria for and with a score of >= 150 on the symptom severity scale. Interventions: For three weeks either waiting list (observation), placebo acupuncture alone ("limited"), or placebo acupuncture with a patient- practitioner relationship augmented by warmth, attention, and confidence ("augmented"). At three weeks, half of the patients were randomly assigned to continue in their originally assigned group for an additional three weeks. Main outcome measures Global improvement scale (range 1-7), adequate relief of symptoms, symptom severity score, and quality of life. Results: At three weeks, scores on the global improvement scale were 3.8 (SD 1.0) v 4.3 (SD 1.4) v 5.0 (SD 1.3) for waiting list versus "limited" versus "augmented," respectively (P < 0.001 for trend). The proportion of patients reporting adequate relief showed a similar pattern: 28 % on waiting list, 44 % in limited group, and 62 % in augmented group (P < 0.001 for trend). The same trend in response existed in symptom severity score (30 (63) v 42 (67) v 82 (89), P < 0.001) and quality of life (3.6 (8.1) v 4.1 (9.4) v 9.3 (14.0), P < 0.001). All pairwise comparisons between augmented and limited patient- practitioner relationship were significant: global improvement scale (P < 0.001), adequate relief of symptoms (P < 0.001), symptom severity score (P = 0.007), quality of life (P = 0.01). Results were similar at six week follow-up. Conclusion Factors contributing to the placebo effect can be progressively combined in a manner resembling a graded dose escalation of component parts. Non-specific effects can produce statistically and clinically significant outcomes and the patient- practitioner relationship is the most robust component.
引用
收藏
页码:41 / 42
页数:3
相关论文
共 50 条
  • [1] Components of Placebo Effect: Randomised Controlled Trial in Patients with Irritable Bowel Syndrome
    Ted J. Kaptchuk
    John M. Kelley
    Lisa M. Conboy
    J. Hummelsberger
    Deutsche Zeitschrift für Akupunktur, 2010, 53 (2) : 41 - 42
  • [2] Components of placebo effect: randomised controlled trial inpatients with irritable bowel syndrome
    Kaptchuk, Ted J.
    Kelley, John M.
    Conboy, Lisa A.
    Davis, Roger B.
    Kerr, Catherine E.
    Jacobson, Eric E.
    Kirsch, Irving
    Schyner, Rosa N.
    Nam, Bong Hyun
    Nguyen, Long T.
    Park, Min
    Rivers, Andrea L.
    McManus, Claire
    Kokkotou, Efi
    Drossman, Douglas A.
    Goldman, Peter
    Lembo, Anthony J.
    BMJ-BRITISH MEDICAL JOURNAL, 2008, 336 (7651): : 999 - 1003
  • [3] Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome
    Zhou, Qiqi
    Verne, Meghan L.
    Fields, Jeremy Z.
    Lefante, John J.
    Basra, Sarpreet
    Salameh, Habeeb
    Verne, G. Nicholas
    GUT, 2019, 68 (06) : 996 - 1002
  • [4] Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial
    Camilleri, M
    Northcutt, AR
    Kong, S
    Dukes, GE
    McSorley, D
    Mangel, AW
    LANCET, 2000, 355 (9209): : 1035 - 1040
  • [5] Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial
    Bijkerk, C. J.
    de Wit, N. J.
    Muris, J. W. M.
    Whorwell, P. J.
    Knottnerus, J. A.
    Hoes, A. W.
    BMJ-BRITISH MEDICAL JOURNAL, 2009, 339 : 613 - 615
  • [6] Randomised clinical trial: pregabalin vs placebo for irritable bowel syndrome
    Saito, Yuri A.
    Almazar, Ann E.
    Tilkes, Katherine E.
    Choung, Rok Seon
    Van Norstrand, Michael D.
    Schleck, Cathy D.
    Zinsmeister, Alan R.
    Talley, Nicholas J.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 49 (04) : 389 - 397
  • [7] Placebo effect in patients with irritable bowel syndrome
    Lu, Ching-Liang
    Chang, Full-Young
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2011, 26 : 116 - 118
  • [8] Acupuncture for irritable bowel syndrome - an exploratory randomised controlled trial
    Reynolds, Julie A.
    Bland, J. Martin
    MacPherson, Hugh
    ACUPUNCTURE IN MEDICINE, 2008, 26 (01) : 8 - 16
  • [9] The influence of antibiotics on irritable bowel syndrome: A randomised controlled trial
    Moayyedi, P
    Duffett, S
    Mason, S
    Brown, J
    Axon, ATR
    GASTROENTEROLOGY, 2002, 122 (04) : A465 - A466
  • [10] The influence of antibiotics on irritable bowel syndrome: A randomised controlled trial
    Moayyedi, P
    Duffett, S
    Mason, S
    Brown, J
    Axon, ATR
    GUT, 2002, 50 : A24 - A24